C&G Editor in Chief, Erin Harris

  1. ARM’s State Of The Industry Briefing At JPM 2024 1/9/2024

    Here's a recap of ARM’s CEO Tim Hunt's 2024 State of the Industry Briefing presentation at JPM 2024.

  2. Cell & Gene: The Podcast Episodes From ARM’s 2023 MOTM 12/21/2023

    All three episodes of Cell & Gene: The Podcast recorded at ARM's 2023 Meeting on the Mesa have now aired. Here's a look at my guests and the important CGT topics we discussed.

  3. iCell, Coeptis On FDA’s Investigation Of CAR T Immunotherapies 12/18/2023

    Last month, the FDA stated it was investigating serious risks of T-cell malignancies in patients following treatment with a chimeric antigen receptor (CAR) T-cell therapies. I met up with Yupo Ma M.D., Ph.D. Chief Scientific Officer at iCell Gene Therapeutics, and Dave Mehalick, CEO and Colleen Delaney, M.D., Chief Scientific and Medical Officer at Coeptis Therapeutics to get their reaction to the FDA’s investigation.

  4. Moving Beyond AAV: The Next Generation Of Vectors In CGT 12/11/2023

    We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.

  5. Video Clips From Cell & Gene Live: Optimizing Your Cold Chain For Cell Therapies 11/30/2023

    For your convenience, we’ve broken down our Cell & Gene Live, Optimizing Your Cold Chain for Cell Therapies, into bite-size video clips by topic.

  6. A Sneak Peek At Providence Therapeutics On Cell & Gene: The Podcast 11/29/2023

    On an upcoming episode of Cell & Gene: The Podcast, I talk to Robert Georgantas III, Ph.D., of Providence Therapeutics, about their mRNA vaccine therapies. Here's a preview of our conversation.

  7. Vor Bio Shares Progress For Patients with AML 11/17/2023

    I talked to Dr. Robert Ang, President and Chief Executive Officer at Vor Bio about the company's VBP101 study for trem-cel in patients with acute myeloid leukemia (AML)

  8. The Eye: A Candidate For Modifier Gene Therapy 11/17/2023

    Ocugen's Chairman, CEO and Co-founder, Shankar Musunuri ,Ph.D., MBA, provides an update on OCU400 and other ongoing trials, why the eye is a good target for gene therapy, the outlook for retinal gene therapy, and more.

  9. Video Clips From Cell & Gene Live: Regulating The CGT Workflow To Improve Patient Safety 10/31/2023

    Here is a breakdown of original 60-minute Cell & Gene Live, Regulating the CGT Workflow to Improve Patient Safety, into video segments by topic.

  10. A Sneak Peek At REGENXBIO On Cell & Gene: The Podcast 10/30/2023

    REGENXBIO's CEO, President, and Director, Ken Mills and I sat down to record an upcoming episode of Cell & Gene: The Podcast. Here's a sneak peak of the episode.